Venture Valuation and Financial Models

Dr. Mark Treherne

Chairperson of Talisman TX, former CEO of the Life Sciences Organisation of UK Trade & Investment, Curriculum Co-ordinator, BBI Cambridge, Cambridge UK.

Commercial research scientist with 30 years' experience in the discovery and diagnosis of novel treatments for diseases with unmet medical need. Formerly at Pfizer and responsible for research into neurodegenerative diseases in the UK. Subsequently, set up Cambridge Drug Discovery as a co-founder and Chief Executive in 1997, which was sold to BioFocus plc in 2001 and then to Charles River. Former CEO for the Department of International Trade in life Sciences, United Kingdom.

Since then, helped to raise £300 million mostly for early-stage life sciences companies and enabled inward investment into the UK of over £6 billion. Now served on the boards of multiple therapeutics, research services and diagnostics companies worldwide. Worked with teams to out licence therapeutic assets over the last 25 years for upfront payments, milestones and future royalties exceeding £1.5 billion. More recent focus on digital biomarkers at Monument Tx and gene therapy at Spliceor, as well as near-term, revenue-generating companies, such as Talisman, Ubiquigent and NuVision.

Participants will gain practical knowledge in topics including:

• Core valuation frameworks - Discounted Cash Flow (DCF), comparable company analysis, and venture capital methods

• Structuring revenue forecasts, cost dynamics, and funding requirement models

• Translating scientific and operational milestones into investor‑ready projections

• Scenario planning to manage uncertainty in early‑stage ventures

By the end of the seminar participants will be able to evaluate investment opportunities, prepare compelling financial models, and make informed strategic choices for venture success.

16:30 - Welcome and Introductions

16:45 - Key note - Company Venture Valuation and Financial Models

17:30 - Q&A with the audience

18:15 - Closing Remarks

This seminar is relevant for professionals such as:

• Life sciences executives and senior leaders

• Corporate strategy, business development, and investment professionals

• Venture capital, private equity, and finance professionals

• R&D and commercial leaders involved in innovation strategy

Designed for leaders who require actionable financial insight without long‑form coursework. No advanced finance background is required - the session focuses on practical application.

Participants join more than a webinar - they benefit from a focused executive learning experience that delivers:

• Strategic frameworks grounded in real life sciences markets

• Interactive Q&A with a domain expert

• Insights tailored to professional leadership and innovation challenges

• Access to the recorded seminar for later review

• Connection to the global BBI Cambridge professional network

• Live participation in the interactive seminar

• Recording of the session - available after the event

• Concise takeaway summary frameworks

• Access to community resources and future sessions